Physician profile
Amitkumar Patel
NPI 1114128758
$69,864.15
in general payments reported to CMS, 2019-2025
42 companies · $1,583 in 2025
The $1,583 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,147 · 2020: $9,814 · 2021: $23K · 2022: $5,414 · 2023: $16K · 2024: $13K · 2025: $1,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $5,595 · Travel and Lodging: $569 · Education: $81.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,050.00 |
| Food and Beverage | $5,595.42 |
| Travel and Lodging | $569.31 |
| Education | $81.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $62,855.14 | 2019-2025 | Lokelma, Farxiga, Flumist Quadrivalent |
| Bayer Healthcare Pharmaceuticals INC. | $736.83 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $702.27 | 2019-2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $694.03 | 2020-2025 | |
| Amgen INC. | $562.97 | 2021-2025 | Krystexxa, Tavneos, Evenity |
| Horizon Therapeutics Plc | $549.15 | 2019-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $503.05 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $403.48 | 2020-2025 | Acthar, Terlivaz |
| Glaxosmithkline, LLC. | $330.50 | 2019-2024 | Arexvy, Jesduvroq |
| Travere Therapeutics, INC. | $254.62 | 2022-2025 | |
| Novo Nordisk INC | $245.38 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.64 | 2023-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $180.54 | 2022-2025 | Velphoro, Velphoro |
| Coloplast Corp | $172.65 | 2019-2023 | |
| Aurinia Pharma U.S., INC. | $160.67 | 2021-2023 | Lupkynis |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amitkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.